argenx Highlights Strategic Priorities for 2022
Published on: Thursday 06 January 2022
Expect data from five registrational trials of efgartigimod by first quarter of 2023 Announcing four new efgartigimod indications to be initiated in 2022: membranous nephropathy, lupus nephritis, ...
